# A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure

> **NCT01125514** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Aliskiren 150 mg
- **DRUG:** Furosemide 60 mg
- **DRUG:** Placebo for Aliskiren
- **DRUG:** Aliskiren 300 mg

## Key facts

- **NCT ID:** NCT01125514
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2012-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125514, "A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01125514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*